These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15554350)

  • 1. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients.
    Coban E; Sari R
    Endocr Res; 2004 Aug; 30(3):343-9. PubMed ID: 15554350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.
    Coban E; Ozdogan M; Yazicioglu G; Sari R
    Int J Clin Pract; 2005 Apr; 59(4):415-8. PubMed ID: 15853856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.
    Phuntuwate W; Suthisisang C; Koanantakul B; Chaloeiphap P; Mackness B; Mackness M
    Atherosclerosis; 2008 Jan; 196(1):122-128. PubMed ID: 17412348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of fenofibrate on insulin sensitivity and plasma lipid profile in non-diabetic males with low high density lipoprotein/dyslipidaemic syndrome.
    Yong QW; Thavintharan S; Cheng A; Chew LS
    Ann Acad Med Singap; 1999 Nov; 28(6):778-82. PubMed ID: 10672386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
    Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
    J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I; Laperrière L; Dzavik V; Tremblay G; Bourgeois J; Després JP
    Atherosclerosis; 2002 Jun; 162(2):363-71. PubMed ID: 11996956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extralipid effects of micronized fenofibrate in dyslipidemic patients.
    Okopień B; Haberka M; Madej A; Belowski D; Labuzek K; Krysiak R; Zieliński M; Basiak M; Herman ZS
    Pharmacol Rep; 2006; 58(5):729-35. PubMed ID: 17085865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
    Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.
    Sasaki J; Yamamoto K; Ageta M
    Clin Ther; 2002 Oct; 24(10):1614-26. PubMed ID: 12462290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol.
    Heller FR; Desager JP; Harvengt C
    Metabolism; 1981 Jan; 30(1):67-71. PubMed ID: 7464555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I; Salomon H; Després JP
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
    Adkins JC; Faulds D
    Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
    Winegar DA; Brown PJ; Wilkison WO; Lewis MC; Ott RJ; Tong WQ; Brown HR; Lehmann JM; Kliewer SA; Plunket KD; Way JM; Bodkin NL; Hansen BC
    J Lipid Res; 2001 Oct; 42(10):1543-51. PubMed ID: 11590209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.